Teresa Marie Bitetti

CIK: 0001977608

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TAK

TAKEDA PHARMACEUTICAL CO LTD

Officer

AURA

Aura Biosciences, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TAK
TAKEDA PHARMACEUTICAL CO LTD
Aug 10, 2026
Sale(S)
Direct
50K shares at avg. $17.10$855K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Jul 1, 2026
Award(A)
Direct
43.9K shares-
AURA
Aura Biosciences, Inc.
Jun 11, 2026
Award(A)
Direct
15K shares-
TAK
TAKEDA PHARMACEUTICAL CO LTD
Apr 27, 2026
Award(A)
Direct
65K shares-
AURA
Aura Biosciences, Inc.
Mar 31, 2025
Award(A)
Direct
21K shares-

		Type	Shares	Price		Ownership
Aug 10, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	50,012	$17.10	$855,205	Direct
Jul 1, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	43,886	-	$0	Direct
Jun 11, 2026	AURA Aura Biosciences, Inc.	Award(A)	15,000	-	$0	Direct
Apr 27, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	64,988	-	$0	Direct
Mar 31, 2025	AURA Aura Biosciences, Inc.	Award(A)	21,000	-	-	Direct

1-5 of 5 transactions

About Bitetti Teresa Marie

Bitetti Teresa Marie (SEC CIK 0001977608) files insider reports with the SEC as President, OBU of TAKEDA PHARMACEUTICAL CO LTD (TAK) and Director of Aura Biosciences, Inc. (AURA).

Signal8 holds 7 ownership filings by Bitetti Teresa Marie (2 Form 3, 5 Form 4), filed between Apr 2, 2025 and Aug 12, 2026. Those filings report 5 transactions, from Mar 31, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bitetti Teresa Marie's filings is in CAMBRIDGE, MA.

Recent filings by Bitetti Teresa Marie

Aug 10, 2026: Open-market sale of TAK shares (Form 4, code S).
Jul 1, 2026: Grant or award of TAK shares (Form 4, code A).
Jun 11, 2026: Grant or award of AURA shares (Form 4, code A).
Apr 27, 2026: Grant or award of TAK shares (Form 4, code A).
Mar 31, 2025: Grant or award of AURA shares (Form 4, code A).

Other insiders filing for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Duprey Lauren Rusckowski, Chief Transformation Officer
Plump Andrew Stewart, President, R&D
Greenway Nicola Deidre Petal, Chief Human Resources Officer
Farajallah Awny Samaan Botros, Chief Medical Officer
Ibrahim Ramy Riad Ahmed, President, PDT BU
Pacheco Rhonda Janice, President, U.S. Business Unit

How to read Form 4 transaction codes